This randomized clinical trial compares the seroprotection response achieved with a 2-dose and a 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant vs a conventional 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant in people with HIV and prior nonresponse to hepatitis B vaccine.
Source link
